On Monday, Shares of Johnson & Johnson (NYSE:JNJ) gained 0.58% to $125.72. The share price is trading in a range of $124.93 – 125.81. The stock exchanged hands with 5.37 million shares contrast to its average daily volume of 6.46 million shares.
Johnson & Johnson (NYSE:JNJ) have shown a high EPS growth of 11.20% in the last 5 years and has earnings growth of 20.10% yoy. Analysts have a mean recommendation of 2.50 on this stock (A rating of less than 2 means buy, “hold” within the 3 range, “sell” within the 4 range, and “strong sell” within the 5 range). The stock appeared -2.54% below its 52-week highs and is up 11.20% for the last five trades.
Shares of Synergy Pharmaceuticals Inc (NASDAQ:SGYP) declined -2.86% to $4.42. The share price of the stock surged 36.00% for the year.
Synergy Pharmaceuticals Inc. (SGYP) declared that Gary G. Gemignani has been designated as Executive Vice President and Chief Financial Officer, effective April 17, 2017. Mr. Gemignani replaces Senior Vice President, Finance, Bernard Denoyer, who will assist in the transition process until his retirement on July 1, 2017.
Mr. Gemignani’s career in healthcare spans over three decades, counting senior administration positions at several pharmaceutical and biopharmaceutical companies. Most recently, he served as Chief Executive Officer and Chief Financial Officer of Biodel, Inc., (now Albireo), overseeing business and planned planning, operations, and financing activities of the Company. During his tenure, Mr. Gemignani successfully led the reverse merger with Albireo and managed several corporate restructurings to strengthen Albireo’s overall financial position. Before this role, Mr. Gemignani served in senior and executive financial and operational roles with multiple public and private companies counting Coronado Biosciences, Inc., Gentium S.p.A., Novartis Pharmaceutical Corp. and Wyeth. Mr. Gemignani began his career with Arthur Andersen and Company and holds a Bachelor’s of Science from St. Peter’s College.
Gary Gemignani’s appointment as EVP and CFO comes with the declarement of the impending retirement of Bernard Denoyer, Senior Vice President, Finance of Synergy Pharmaceuticals. Mr. Denoyer has been with Synergy from its outset as a public company in July, 2008, and has made lasting contributions to the company.
Analysts give SGYP a mean recommendation of 2.00. The company has dropped -34.32% in past 3 months and in the last five trades has moved up 3.76%. The stock has earnings growth of -16.80% yoy and showed a low EPS growth of -31.80% over the past five years. The stock’s price moved down its 200-day moving average of $5.43. The stock is presently trading down its SMA-50 of $4.93.